Circulating Tumor Cells Correlating with Ki-67 Predicts the Prognosis of Bladder Cancer Patients

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2022 Nov 5

PMID 36334226

Authors

Jie Liu

Cailing Ma

Xiaohang Li

Anan Li

Zhiyong Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the value of circulating tumor cells (CTCs) and Ki-67 in predicting the prognosis of bladder cancer. Here, we tested CTC counts and Ki-67 levels to assess patient prognosis.

Methods: 84 patients with bladder cancer who underwent surgery were included in this study. Peripheral blood CTCs were detected by SE-iFISH technology before and after surgery, and Ki-67 levels were analyzed by immunohistochemistry. The association between CTCs and Ki-67 and the combination of the two was analyzed to predict the prognosis of patients.

Results: 76 out of 84 patients (90.5%) were positive. ROC curve analysis showed that preoperative and postoperative CTC counts = 4 and 2 were the best thresholds for predicting patient recurrence or death. In multivariate analysis, high postoperative CTC count (≥ 2) (P < 0.001) and Ki-67 high expression (≥ 15%) (P < 0.001) were independent poor prognostic factors for PFS in bladder cancer patients. In addition, the study found that Ki-67 levels were positively correlated with high postoperative CTC counts, Bladder cancer patients with Ki-67 high expression and high postoperative CTC counts were associated with extremely poor progression-free survival.

Conclusion: Ki-67 high expression is associated with high postoperative CTC counts, both of which predict poor prognosis in bladder cancer patients.

Citing Articles

A revolutionary era in advancing precision immuno-oncology; role of circulating tumor cells.

Bahmaie N, Ozensoy Guler O, Simsek E J Liq Biopsy. 2025; 6:100169.

PMID: 40027303 PMC: 11863822. DOI: 10.1016/j.jlb.2024.100169.

Predicting recurrence of non-muscle invasive bladder urothelial carcinoma: predictive value of the optimal cut-off value of Ki67.

Peng R, Zhang Y, Jia M, Yi X, Yi X, Li S Front Oncol. 2025; 14:1522009.

PMID: 39886663 PMC: 11779619. DOI: 10.3389/fonc.2024.1522009.

Utility of F-FDG PET/CT metabolic parameters on post-transplant lymphoproliferative disorder diagnosis.

Zhang G, Shen J, Hu T, Zheng W, Jia Q, Tan J Ann Nucl Med. 2025; .

PMID: 39826002 DOI: 10.1007/s12149-025-02016-9.

Detection and identification of circulating tumor cells in parathyroid tumors and correlation analysis with clinicopathological features.

Wang J, Jiang X, Wang Q, Zhao T, Shen H, Liu X Endocrine. 2024; 85(3):1357-1364.

PMID: 38730070 DOI: 10.1007/s12020-024-03831-2.

Prediction of Ki-67 expression in bladder cancer based on CT radiomics nomogram.

Feng S, Zhou D, Li Y, Yuan R, Kong J, Jiang F Front Oncol. 2024; 14:1276526.

PMID: 38482209 PMC: 10932959. DOI: 10.3389/fonc.2024.1276526.

References

Chen Y, Yang Z, Wang Y, Wang J, Wang C . Karyotyping of circulating tumor cells for predicting chemotherapeutic sensitivity and efficacy in patients with esophageal cancer. BMC Cancer. 2019; 19(1):651. PMC: 6609398. DOI: 10.1186/s12885-019-5850-7. View

Maly V, Maly O, Kolostova K, Bobek V . Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer. In Vivo. 2019; 33(4):1027-1037. PMC: 6689346. DOI: 10.21873/invivo.11571. View

Fu G, Cheng K, Chen A, Xu Z, Chen X, Tian J . Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer. Front Oncol. 2021; 11:701298. PMC: 8222714. DOI: 10.3389/fonc.2021.701298. View

Song J, Yu Z, Dong B, Zhu M, Guo X, Ma Y . Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma. World J Surg Oncol. 2021; 19(1):156. PMC: 8152311. DOI: 10.1186/s12957-021-02268-5. View

Lin P, Gires O, Wang D, Li L, Wang H . Comprehensive in situ co-detection of aneuploid circulating endothelial and tumor cells. Sci Rep. 2017; 7(1):9789. PMC: 5575124. DOI: 10.1038/s41598-017-10763-7. View

Rubino S, Kim Y, Zhou J, Dhilon J, Li R, Spiess P . Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. World J Urol. 2020; 39(5):1539-1547. PMC: 10091226. DOI: 10.1007/s00345-020-03342-5. View

Bu J, Kang Y, Lee Y, Kim J, Cho Y, Moon B . Lab on a fabric: Mass producible and low-cost fabric filters for the high-throughput viable isolation of circulating tumor cells. Biosens Bioelectron. 2017; 91:747-755. DOI: 10.1016/j.bios.2017.01.039. View

Lee A, Endesfelder D, Rowan A, Walther A, Birkbak N, Futreal P . Chromosomal instability confers intrinsic multidrug resistance. Cancer Res. 2011; 71(5):1858-70. PMC: 3059493. DOI: 10.1158/0008-5472.CAN-10-3604. View

Ziaran S, Harsanyi S, Bevizova K, Novakova Z, Trebaticky B, Bujdak P . Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence. Eur J Histochem. 2020; 64(2). PMC: 7118433. DOI: 10.4081/ejh.2020.3098. View

10.

Rink M, Lee D, Kent M, Xylinas E, Fritsche H, Babjuk M . Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU Int. 2012; 111(3 Pt B):E30-6. DOI: 10.1111/j.1464-410X.2012.11433.x. View

11.

Cobain E, Paoletti C, Smerage J, Hayes D . Clinical Applications of Circulating Tumor Cells in Breast Cancer. Recent Results Cancer Res. 2019; 215:147-160. DOI: 10.1007/978-3-030-26439-0_8. View

12.

Wang P, Xu Y, Sun Y, Cheng J, Zhou K, Wu S . Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. Liver Int. 2020; 41(3):562-573. DOI: 10.1111/liv.14734. View

13.

Wang L, Li Y, Xu J, Zhang A, Wang X, Tang R . Quantified postsurgical small cell size CTCs and EpCAM circulating tumor stem cells with cytogenetic abnormalities in hepatocellular carcinoma patients determine cancer relapse. Cancer Lett. 2017; 412:99-107. DOI: 10.1016/j.canlet.2017.10.004. View

14.

Wang Y, Liu Y, Zhang L, Tong L, Gao Y, Hu F . Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer. J Cancer Res Clin Oncol. 2019; 145(12):2911-2920. PMC: 6861204. DOI: 10.1007/s00432-019-03040-9. View

15.

Cieslikowski W, Antczak A, Nowicki M, Zabel M, Budna-Tukan J . Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management. Biomedicines. 2021; 9(9). PMC: 8471111. DOI: 10.3390/biomedicines9091179. View

16.

Li Y, Zhang X, Ge S, Gao J, Gong J, Lu M . Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. Oncotarget. 2014; 5(16):6594-602. PMC: 4196148. DOI: 10.18632/oncotarget.2175. View

17.

van Rhijn B, Burger M, Lotan Y, Solsona E, Stief C, Sylvester R . Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009; 56(3):430-42. DOI: 10.1016/j.eururo.2009.06.028. View

18.

Babjuk M, Burger M, Capoun O, Cohen D, Comperat E, Dominguez Escrig J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2021; 81(1):75-94. DOI: 10.1016/j.eururo.2021.08.010. View

19.

Nicolazzo C, Busetto G, Gradilone A, Sperduti I, Del Giudice F, Loreni F . Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial. Oncologist. 2019; 24(5):612-616. PMC: 6516110. DOI: 10.1634/theoncologist.2018-0784. View

20.

Lin P . Aneuploid CTC and CEC. Diagnostics (Basel). 2018; 8(2). PMC: 6023477. DOI: 10.3390/diagnostics8020026. View